The definition and estimated prevalence rate of rare diseases vary in different areas. The World Health Organization (WHO) defines a rare disease as a disease with incidence ranging from 0.65 to 1‰ in the total population. 1 In Europe, rare disease stands for a disease affecting less than 5 in 10 000 persons each year, whereas in the United States, it is a disease affecting less than 200 000 persons in the whole country. 1 In China, rare disease is loosely defined as a disease with a prevalence rate lower than 1/500 000 in the population or less than 1/10 000 in neonates. 1 Up to 16.8 million patients with rare diseases were estimated in China, which poses a major public health challenge to the national medical care system. 1Although there is no universal definition for rare liver diseases, autoimmune and genetic liver diseases have long been considered to be rare. As a result of increasing awareness of these diseases and improving availability of autoantibody and genetic tests, more and more cases have been identified in their early stage or even in the pre-symptomatic phase, resulting in a transition of liver diseases spectrum in China (Figure 1). In this mini-review, we will summarize the epidemiological profiles of rare liver diseases mainly including autoimmune and inherited metabolic liver diseases in China to provide new insight into the global liver disease burden (Table 1).
| PRIMARY B ILIARY CHOL ANG ITIS (PBC)PBC is an autoimmune liver disease typically affecting middle-aged women. PBC patients often present with elevation of serum alkaline phosphatase (ALP)/gamma-glutamyl transferase (GGT), positive antimitochondrial antibodies (AMAs) and chronic intra-hepatic cholestatic injury. Meta-analysis showed that the global prevalence of PBC was reported to be 146 per million persons, with prevalence in the North America, Europe and Asia-Pacific regions being 218, 145 and 98 per million persons respectively. 2 Of note, within the Asia-Pacific region, China and Japan have the highest prevalence, followed by New Zealand, South Korea and Australia. 3 One population-based study in Hongkong, China has estimated the average age-/sex-adjusted rates of PBC, with a prevalence of